Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of ...
November 06 2019 - 9:02AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic
chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer,
today announced that it will present data supporting its AlloCAR T
pipeline during the 61st American Society of Hematology (ASH)
Annual Meeting & Exposition taking place December 7 – 10 at the
Orange County Convention Center (OCCC) in Orlando, FL.
“These pre-clinical studies further illustrate the potential of
our AlloCAR T pipeline across multiple antigen targets and types of
blood cancer and will support the expansion of our pipeline of
‘off-the-shelf’ CAR T cell therapies,” said Rafael Amado, M.D.,
Executive Vice President of Research & Development and Chief
Medical Officer of Allogene.
The ASH abstracts are now available at www.hematology.org. The
presentations will include additional data not available in the
abstracts. Details are as follows.
Allogene Poster Presentations
Session: 653. Myeloma: Therapy, Excluding
Transplantation: Poster IAbstract
#1834Title: Allogeneic Anti-BCMA CAR-T Cells Show
Tumour Specific Killing Against Primary Multiple Myeloma Cells from
Different Genomic Sub-GroupsPresenter: Ana Martins
Metelo, Ph.D., King’s College Hospital, LondonSession Date
& Time: Saturday, December 7, 2019; 5:30 – 7:30
p.m.Location: Orange County Convention Center,
Hall B
ALLO-715 is currently in Phase 1 development. The
investigational therapy utilizes TALEN® gene-editing technology
pioneered and owned by Cellectis. Allogene has an exclusive license
to the Cellectis technology for allogeneic products directed at the
BCMA target. Allogene holds global development and commercial
rights for this investigational candidate.
Session: 616. Acute Myeloid Leukemia: Novel
Therapy, Excluding Transplantation: Poster
IIIAbstract #3921Title:
Preclinical Evaluation of ALLO-819, an Allogeneic CAR T Cell
Therapy Targeting FLT3 for the Treatment of Acute Myeloid
LeukemiaPresenter: Cesar Sommer, Ph.D., Allogene
TherapeuticsSession Date & Time: Monday,
December 9, 2019; 6 – 8 p.m.Location: Orange
County Convention Center, Hall B
ALLO-819 utilizes TALEN® gene-editing technology pioneered and
owned by Cellectis, and Allogene has an exclusive license to the
Cellectis technology for allogeneic products directed at the FLT3
target. Allogene holds global development and commercial rights to
the FLT3 AlloCAR T program candidate.
Poster Presentation in Collaboration with Development
PartnerUCART19, sponsored by Servier, is in Phase 1
development for the treatment of relapsed/refractory acute
lymphoblastic leukemia (ALL).
Session: 703. Adoptive Immunotherapy:
Mechanisms and New Approaches: Poster IIAbstract
#3228Title: Allogeneic Anti-CD19 CAR T Cells
Manufactured from Healthy Donors Provide a Unique Cellular Product
with Distinct Phenotypic Characteristics Compared to CAR T Cells
Generated from Patients with Mature B Cell
MalignanciesPresenter: Charlotte Graham, MRCP,
FRCPath, King’s College Hospital, LondonSession Date &
Time: Sunday, December 8, 2019; 6 – 8
p.m.Location: Orange County Convention Center,
Hall B
UCART19 is being jointly developed under
a clinical development collaboration between Servier and
Allogene based on an exclusive license granted by Cellectis to
Servier. UCART19 utilizes TALEN® gene-editing technology
pioneered and owned by Cellectis. Servier grants
to Allogene exclusive rights to UCART19 in the U.S. while
Servier retains exclusive rights for all other countries.
About Allogene Therapeutics Allogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) therapies for cancer. Led by a world-class management
team with significant experience in cell therapy, Allogene is
developing a pipeline of “off-the-shelf” CAR T cell
therapy candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and
at greater scale to more patients. For more information,
please visit www.allogene.com, and follow @AllogeneTx on
Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The press release may, in some cases, use terms
such as "predicts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements
include statements regarding intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the ability to progress the research and development of
ALLO-715 and ALLO-819, and the ability of Servier and Allogene to
progress the research and development of UCART19, and the potential
benefits of AlloCAR T therapy. Various factors may cause
differences between Allogene’s expectations and actual results as
discussed in greater detail in Allogene’s filings with
the Securities and Exchange Commission (SEC), including
without limitation in its Form 10-Q for the quarter
ended September 30, 2019. Any forward-looking statements that
are made in this press release speak only as of the date of this
press release. Allogene assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
1 Servier is an independent international pharmaceutical
company, governed by a foundation, with Headquarters based in
France
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2024 to May 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From May 2023 to May 2024